ArticleThe oncologist2026
Clinical and molecular response to vorasidenib in post-transplant patient with IDH2-mutant intrahepatic cholangiocarcinoma.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIDH2 mutations occur in a small subset of intrahepatic cholangiocarcinoma and currently lack approved targeted therapies. CASE PRESENTATION: We report a post-transplant patient with IDH2-mutant intrahepatic cholangiocarcinoma who developed recurrent disease following multiple treatments for hepatocellular carcinoma and subsequent liver transplantation. Comprehensive genomic profiling revealed an IDH2 p. R172K mutation. Given limited treatment options and contraindications to immunotherapy, off-label treatment with the dual IDH1/2 inhibitor vorasidenib was initiated.
resultsThe patient achieved a durable radiographic and molecular response, with a reduction in circulating tumor DNA and a partial response by RECIST criteria sustained for approximately 1 year.
conclusionThis case highlights the potential clinical relevance of IDH-directed therapy in IDH2-mutant cholangiocarcinoma and demonstrates feasibility in an immunosuppressed post-transplant setting. These findings are hypothesis-generating and support further evaluation of IDH inhibition in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.